Previous Close | 1.8750 |
Open | 2.0600 |
Bid | 1.8300 x 600 |
Ask | 1.8800 x 600 |
Day's Range | 1.8050 - 1.9500 |
52 Week Range | 1.1000 - 7.5000 |
Volume | |
Avg. Volume | 1,406,769 |
Market Cap | 152.425M |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.3100 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.00 |
REDWOOD CITY, Calif. & BOSTON, April 22, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the AS
REDWOOD CITY, Calif. & BOSTON, April 08, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.
REDWOOD CITY, Calif. & BOSTON, March 28, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.